Literature DB >> 15599678

Effectiveness of intrapericardial administration of streptokinase in purulent pericarditis.

Witold Zbyszek Tomkowski1, Renata Gralec, Paweł Kuca, Janusz Burakowski, Tadeusz Orłowski, Marcin Kurzyna.   

Abstract

BACKGROUND AND
PURPOSE: Purulent pericarditis is very rare. However, among patients suffering from this disease the mortality rate is very high. The aim of this study was to evaluate the effectiveness and side effects of intrapericardial streptokinase administration in patients with confirmed purulent pericarditis. PATIENTS AND METHODS: Three patients, one 50-year-old man and two women aged 64 and 40 years, who were admitted to the intensive care unit (ICU) due to purulent pericarditis, entered the study. In all three cases a subxiphoid pericardiotomy followed by insertion of a drainage line into the pericardial space was performed. Antibiotic therapy was started immediately on admission to the hospital. Despite continued antibiotic therapy in all three patients, daily drainage from the pericardium--during several days after surgery--staggered between 50-200 ml/day. Due to considerable purulent pericardial drainage loculations and/or fibrin deposits confirmed by echocardiography, streptokinase (500,000 IU dissolved in 50 ml of normal saline) was administered into the pericardial space over 10 min, using the previously inserted drainage catheter. This regimen was repeated after 12 and 24 h. The total dose of streptokinase was 1,500,000 IU.
RESULTS: The clinical effect of intrapericardial streptokinase administration was excellent. Several days after intrapericardial administration of streptokinase, drainage of purulent pericardial fluid stopped. No complications associated with intrapericardial streptokinase administration were observed. In the follow-up echocardiography (in two patients repeated 6 and 9 months after delivery of streptokinase), pericardial fluid and echocardiographic signs of pericardial constriction were not observed.
CONCLUSION: Intrapericardial administration of streptokinase in purulent pericarditis is effective and safe.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15599678     DOI: 10.1007/s00059-004-2655-4

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  8 in total

1.  Pyogenic Pericarditis and Cardiac Tamponade Due to Streptococcus anginosus in a Combat Theater.

Authors:  Ryan C Maves; Michael S Tripp; Tracy Franzos; Scott C Wallace; Benjamin J Drinkwine; Todd C Villines
Journal:  Open Forum Infect Dis       Date:  2017-02-10       Impact factor: 3.835

2.  Pericardioscopy and epi- and pericardial biopsy - a new window to the heart improving etiological diagnoses and permitting targeted intrapericardial therapy.

Authors:  Bernhard Maisch; Heinz Rupp; Arsen Ristic; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-05       Impact factor: 4.214

3.  Acute purulent pericarditis treated conservatively with intrapericardial fibrinolysis and intrapericardial and systemic antibiotics.

Authors:  Mahmoud Abdelnabi; Abdallah Almaghraby; Yehia Saleh; Alyaa El Sayed; Judy Rizk
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-03-05

Review 4.  Clinical review: intrapericardial fibrinolysis in management of purulent pericarditis.

Authors:  Pascal Augustin; Mathieu Desmard; Pierre Mordant; Sigismond Lasocki; Jean-Michel Maury; Nicholas Heming; Philippe Montravers
Journal:  Crit Care       Date:  2011-04-20       Impact factor: 9.097

5.  Therapeutic payload delivery to the myocardium: Evolving strategies and obstacles.

Authors:  Tarek Shazly; Arianna Smith; Mark J Uline; Francis G Spinale
Journal:  JTCVS Open       Date:  2022-05-05

6.  Intrapericardial fibrinolysis in purulent pericarditis-case report.

Authors:  Małgorzata Dybowska; Barbara Kazanecka; Paweł Kuca; Janusz Burakowski; Cezary Czajka; Franciszek Grzegorczyk; Renata Gralec; Witold Tomkowski
Journal:  Int J Emerg Med       Date:  2015-10-07

7.  Primary purulent bacterial pericarditis due to Streptococcus intermedius in an immunocompetent adult: a case report.

Authors:  Mohammad Saud Khan; Zubair Khan; Bhavana Siddegowda Banglore; Ghattas Alkhoury; Laura Murphy; Claudiu Georgescu
Journal:  J Med Case Rep       Date:  2018-02-05

8.  Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series.

Authors:  Małgorzata Dybowska; Monika Szturmowicz; Lucyna Opoka; Piotr Rudziński; Witold Tomkowski
Journal:  BMC Cardiovasc Disord       Date:  2020-08-27       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.